Potential transaction value exceeds US$1.3 billion Kelun Pharmaceuticals and Merck & Co. reach an oncology drug authorization cooperation Post date May 16, 2022 — 20:13 Post Lock Read More Potential Transaction Amount Over US$1.3 Billion Cologne Pharmaceuticals and Merck & Co. Reach an Oncology Drug Licensing Partnership Oncology Post date May 16, 2022 — 20:07 Post Lock Read More Potential transaction value exceeds US$1.3 billion Kelun Pharmaceuticals and Merck & Co. reach an oncology drug authorization cooperation Post date May 16, 2022 — 19:52 Post Lock Read More Weixinkang has been surveyed by 5 institutions: In the future, with the gradual increase in the coverage of 12V hospitals, it will bring continuous business growth to the company, which is the first curve of business growth (with survey questions and answers) Post date May 16, 2022 — 12:55 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Zhongcai.com Post date May 14, 2022 — 15:06 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022- Post date May 14, 2022 — 13:06 Post Lock Read More Challenges and Opportunities of Allergy Track, How "Old" Industries Can Revitalize "New" Vitality Post date May 13, 2022 — 21:50 Post Lock Read More Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Potential Transaction Amount Over US$1.3 Billion Cologne Pharmaceuticals and Merck & Co. Reach an Oncology Drug Licensing Partnership Oncology Post date May 16, 2022 — 20:07 Post Lock Read More Potential transaction value exceeds US$1.3 billion Kelun Pharmaceuticals and Merck & Co. reach an oncology drug authorization cooperation Post date May 16, 2022 — 19:52 Post Lock Read More Weixinkang has been surveyed by 5 institutions: In the future, with the gradual increase in the coverage of 12V hospitals, it will bring continuous business growth to the company, which is the first curve of business growth (with survey questions and answers) Post date May 16, 2022 — 12:55 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Zhongcai.com Post date May 14, 2022 — 15:06 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022- Post date May 14, 2022 — 13:06 Post Lock Read More Challenges and Opportunities of Allergy Track, How "Old" Industries Can Revitalize "New" Vitality Post date May 13, 2022 — 21:50 Post Lock Read More Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Potential transaction value exceeds US$1.3 billion Kelun Pharmaceuticals and Merck & Co. reach an oncology drug authorization cooperation Post date May 16, 2022 — 19:52 Post Lock Read More Weixinkang has been surveyed by 5 institutions: In the future, with the gradual increase in the coverage of 12V hospitals, it will bring continuous business growth to the company, which is the first curve of business growth (with survey questions and answers) Post date May 16, 2022 — 12:55 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Zhongcai.com Post date May 14, 2022 — 15:06 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022- Post date May 14, 2022 — 13:06 Post Lock Read More Challenges and Opportunities of Allergy Track, How "Old" Industries Can Revitalize "New" Vitality Post date May 13, 2022 — 21:50 Post Lock Read More Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Weixinkang has been surveyed by 5 institutions: In the future, with the gradual increase in the coverage of 12V hospitals, it will bring continuous business growth to the company, which is the first curve of business growth (with survey questions and answers) Post date May 16, 2022 — 12:55 Post Lock Read More The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Zhongcai.com Post date May 14, 2022 — 15:06 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022- Post date May 14, 2022 — 13:06 Post Lock Read More Challenges and Opportunities of Allergy Track, How "Old" Industries Can Revitalize "New" Vitality Post date May 13, 2022 — 21:50 Post Lock Read More Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
The research results of Hengrui Medicine's PD-L1 inhibitor adebelimumab appear in The Lancet Oncology, which is expected to bring new options for patients with small cell lung cancer Post date May 15, 2022 — 08:35 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Zhongcai.com Post date May 14, 2022 — 15:06 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022- Post date May 14, 2022 — 13:06 Post Lock Read More Challenges and Opportunities of Allergy Track, How "Old" Industries Can Revitalize "New" Vitality Post date May 13, 2022 — 21:50 Post Lock Read More Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022 CFi.CN Zhongcai.com Post date May 14, 2022 — 15:06 Post Lock Read More Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022- Post date May 14, 2022 — 13:06 Post Lock Read More Challenges and Opportunities of Allergy Track, How "Old" Industries Can Revitalize "New" Vitality Post date May 13, 2022 — 21:50 Post Lock Read More Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Luoxin Pharmaceutical (002793): Record Form of Investor Relations Activities on May 12, 2022- Post date May 14, 2022 — 13:06 Post Lock Read More Challenges and Opportunities of Allergy Track, How "Old" Industries Can Revitalize "New" Vitality Post date May 13, 2022 — 21:50 Post Lock Read More Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Challenges and Opportunities of Allergy Track, How "Old" Industries Can Revitalize "New" Vitality Post date May 13, 2022 — 21:50 Post Lock Read More Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Institutional research丨Meichang's 12th line of stand-alone machines has completed technical transformation, and the industrial chain has been extended to upstream raw materials; Livzon Group's API business has become a new driving force for development 21 Economic Net Post date May 13, 2022 — 12:57 Post Lock Read More Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Hengrui's "Double Ai" program achieved the primary study endpoint in the international phase III clinical trial Post date May 12, 2022 — 22:14 Post Lock Read More China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
China Resources Double Crane: New crown special medicine brings potential profit increase, R&D innovation promotes long-term growth of the company Xinhua Post date May 10, 2022 — 13:23 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 17:33 Post Lock Read More Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Nuggets Innovative Drugs｜Junshi Bio’s new crown drug is in Phase III clinical trial and Pfizer’s Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Nuggets Innovative Drugs Junshi Bio’s new crown drug is in Phase III clinical trials with Pfizer’s Paxlovid to conduct head-to-head clinical studies of injection monoclonal antibody jqknews Post date May 8, 2022 — 15:50 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical and head-to-head clinical study with Pfizer's Paxlovid_ Oriental Fortune Post date May 8, 2022 — 15:37 Post Lock Read More Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Over 20 domestic pharmaceutical companies deploy PARP inhibitors to target ovarian cancer, the "king of women's cancer" Post date May 8, 2022 — 14:40 Post Lock Read More Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Attacking the "King of Women's Cancer" ovarian cancer, more than 20 domestic pharmaceutical companies deploy PARP inhibitors_Shenzhen Hotline Post date May 8, 2022 — 13:25 Post Lock Read More Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Nuggets for innovative drugs Junshi Bio's new crown drug is in phase III clinical trial and Pfizer's Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:24 Post Lock Read More Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Nuggets for innovative drugs Junshi Bio’s new crown drug is in phase III clinical trial and Pfizer Paxlovid conducts head-to-head clinical research Post date May 8, 2022 — 13:23 Post Lock Read More CGNPC held a 2021 annual results conference Post date May 7, 2022 — 19:43 Post Lock Read More Want to see more data? Registered subscribers can see all the data. Register Now!
Caishen.CoCaishen.Co